S&P 500

6.049,88

0,05%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Amarin Corp PLC (AMRN)
Amarin Corp PLC (AMRN) Notícias

AMRN

Amarin (AMRN)

Amarin Corp PLC

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:AMRN

1 2 3 4 5 6 7 8 9 10 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
22/11/2024	18:49	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AMRN	Amarin Corp PLC
11/11/2024	10:00	GlobeNewswire Inc.	Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual	NASDAQ:AMRN	Amarin Corp PLC
31/10/2024	17:42	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:AMRN	Amarin Corp PLC
30/10/2024	17:10	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:AMRN	Amarin Corp PLC
30/10/2024	17:05	GlobeNewswire Inc.	Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update	NASDAQ:AMRN	Amarin Corp PLC
01/10/2024	09:00	GlobeNewswire Inc.	Amarin Announces Two Upcoming Investor Events	NASDAQ:AMRN	Amarin Corp PLC
09/09/2024	08:30	GlobeNewswire Inc.	Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe	NASDAQ:AMRN	Amarin Corp PLC
22/08/2024	09:30	GlobeNewswire Inc.	Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress	NASDAQ:AMRN	Amarin Corp PLC
05/08/2024	18:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AMRN	Amarin Corp PLC
31/07/2024	08:00	GlobeNewswire Inc.	Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update	NASDAQ:AMRN	Amarin Corp PLC
17/07/2024	17:15	GlobeNewswire Inc.	Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal	NASDAQ:AMRN	Amarin Corp PLC
17/07/2024	09:00	GlobeNewswire Inc.	Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024	NASDAQ:AMRN	Amarin Corp PLC
08/07/2024	08:30	GlobeNewswire Inc.	Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)	NASDAQ:AMRN	Amarin Corp PLC
04/06/2024	08:30	GlobeNewswire Inc.	Amarin Board of Directors Announces CEO Transition	NASDAQ:AMRN	Amarin Corp PLC
28/05/2024	09:15	GlobeNewswire Inc.	Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.	NASDAQ:AMRN	Amarin Corp PLC
06/05/2024	09:00	GlobeNewswire Inc.	Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference	NASDAQ:AMRN	Amarin Corp PLC
01/05/2024	08:00	GlobeNewswire Inc.	Amarin Reports First Quarter 2024 Business Update and Financial Results	NASDAQ:AMRN	Amarin Corp PLC
24/04/2024	15:00	GlobeNewswire Inc.	Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event	NASDAQ:AMRN	Amarin Corp PLC
22/04/2024	09:00	GlobeNewswire Inc.	Amarin Announces Results of Annual General Meeting of Shareholders	NASDAQ:AMRN	Amarin Corp PLC
15/04/2024	09:00	GlobeNewswire Inc.	Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024	NASDAQ:AMRN	Amarin Corp PLC
08/04/2024	09:00	GlobeNewswire Inc.	Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24	NASDAQ:AMRN	Amarin Corp PLC
08/04/2024	07:30	PR Newswire (Canada)	New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	NASDAQ:AMRN	Amarin Corp PLC
06/04/2024	16:30	GlobeNewswire Inc.	New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	NASDAQ:AMRN	Amarin Corp PLC
03/04/2024	09:00	GlobeNewswire Inc.	Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe	NASDAQ:AMRN	Amarin Corp PLC
25/03/2024	09:00	GlobeNewswire Inc.	Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo	NASDAQ:AMRN	Amarin Corp PLC
04/03/2024	19:30	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:AMRN	Amarin Corp PLC
04/03/2024	10:00	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:AMRN	Amarin Corp PLC
29/02/2024	09:06	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:AMRN	Amarin Corp PLC
29/02/2024	09:00	GlobeNewswire Inc.	Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	NASDAQ:AMRN	Amarin Corp PLC
15/02/2024	10:00	GlobeNewswire Inc.	Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024	NASDAQ:AMRN	Amarin Corp PLC